Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Up 3.2% - Here's Why

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report)'s stock price rose 3.2% during mid-day trading on Tuesday . The company traded as high as $5.70 and last traded at $5.59. Approximately 3,312,550 shares changed hands during mid-day trading, a decline of 73% from the average daily volume of 12,046,141 shares. The stock had previously closed at $5.41.

Analyst Ratings Changes

Several equities analysts have weighed in on RXRX shares. Cowen restated a "hold" rating on shares of Recursion Pharmaceuticals in a report on Friday, February 28th. Leerink Partners cut their price objective on Recursion Pharmaceuticals from $7.00 to $6.00 and set a "market perform" rating on the stock in a research note on Friday, February 28th. Morgan Stanley reduced their target price on Recursion Pharmaceuticals from $10.00 to $8.00 and set an "equal weight" rating for the company in a report on Thursday, April 10th. Needham & Company LLC reiterated a "buy" rating and set a $11.00 price target on shares of Recursion Pharmaceuticals in a report on Tuesday, April 8th. Finally, KeyCorp dropped their price target on shares of Recursion Pharmaceuticals from $12.00 to $10.00 and set an "overweight" rating on the stock in a research report on Wednesday, January 8th. Four analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average target price of $8.20.

Recursion Pharmaceuticals Stock Down 0.3 %

The firm has a 50-day moving average of $6.21 and a two-hundred day moving average of $6.78. The firm has a market cap of $2.30 billion, a price-to-earnings ratio of -3.75 and a beta of 1.00. The company has a current ratio of 4.35, a quick ratio of 4.35 and a debt-to-equity ratio of 0.04.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last issued its quarterly earnings results on Friday, February 28th. The company reported ($0.53) EPS for the quarter, missing analysts' consensus estimates of ($0.36) by ($0.17). Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The business had revenue of $4.60 million for the quarter, compared to analyst estimates of $19.04 million. During the same quarter last year, the firm earned ($0.42) earnings per share. The firm's quarterly revenue was down 57.8% compared to the same quarter last year. As a group, sell-side analysts predict that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Recursion Pharmaceuticals

Large investors have recently bought and sold shares of the stock. Decker Retirement Planning Inc. acquired a new position in shares of Recursion Pharmaceuticals during the fourth quarter valued at about $26,000. Private Trust Co. NA acquired a new stake in Recursion Pharmaceuticals during the fourth quarter worth about $27,000. GAMMA Investing LLC increased its stake in Recursion Pharmaceuticals by 1,979.2% during the fourth quarter. GAMMA Investing LLC now owns 5,198 shares of the company's stock valued at $35,000 after acquiring an additional 4,948 shares during the period. Farther Finance Advisors LLC raised its holdings in Recursion Pharmaceuticals by 21.1% in the 4th quarter. Farther Finance Advisors LLC now owns 7,757 shares of the company's stock valued at $52,000 after acquiring an additional 1,353 shares in the last quarter. Finally, NewEdge Advisors LLC lifted its position in shares of Recursion Pharmaceuticals by 43.7% in the 4th quarter. NewEdge Advisors LLC now owns 7,847 shares of the company's stock worth $53,000 after acquiring an additional 2,387 shares during the period. 89.06% of the stock is currently owned by institutional investors and hedge funds.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.